A new twist in cellular resistance to the anticancer drug bleomycin-A5

Current Drug Metabolism

Volumn 11, Issue 7, 2010, Pages 595-602

  Aouida, Mustapha ^a   Ramotar, Dindial ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Bleomycin; Cancer cells; Drug resistance; Substrates; Therapy; Transport

Indexed keywords

ABC TRANSPORTER; BLEOMYCIN A5; BLEOMYCIN CO 57; BLEOMYCIN HYDROLASE; CAMPTOTHECIN; CISPLATIN; ETOPOSIDE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; VESICULAR TRANSPORT ADAPTOR PROTEIN;

CANCER RESISTANCE; CELL KILLING; CELL MEMBRANE; CHROMATIN STRUCTURE; CYTOTOXICITY; DNA BINDING; DNA REPAIR; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; GENE OVEREXPRESSION; GENOTOXICITY; HUMAN; LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; REGULATORY MECHANISM; REVIEW; SQUAMOUS CELL CARCINOMA; TESTIS CANCER; TESTIS CARCINOMA; TREATMENT RESPONSE; UTERINE CERVIX; YEAST; YEAST CELL;

AMINO ACID TRANSPORT SYSTEMS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CARNITINE; CELL MEMBRANE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; ORGANIC CATION TRANSPORT PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE HOMOLOGY, NUCLEIC ACID; SUBSTRATE SPECIFICITY; SYMPORTERS;

EID: 77958073095     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010792927307     Document Type: Review

References (42)

1. Umezawa H. Natural and artificial bleomycins: chemistry and antitumor activities. Pure Appl. Chem., 1971, 28, 665-680.
2. Aouida, M.; Leduc, A.; Wang, H.; Ramotar, D. Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. Biochem. J., 2004, 384, 47-58. (Pubitemid 39564160)
3. Burger, R. M. Cleavage of nucleic acids by bleomycin. Chem. Rev., 1998, 98, 1153-1169.
4. Bennett, R, A.; Swerdlow, P. S.; Povirk, L. F. Spontaneous cleavage of bleomycin-induced abasic sites in chromatin and their mutagenicity in mammalian shuttle vectors. Biochemistry, 1993, 32, 3188-3195.
5. Dar, M. E.; Jorgensen, T. J. Deletions at short direct repeats and base substitutions are characteristic mutations for bleomycin-induced double-and single-strand breaks, respectively, in a human shuttle vector system. Nucleic Acids Res., 1995, 23, 3224-3230.
6. Dorr, R. T.; Meyers, R.; Snead, K.; Liddil, J. D. Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin. Cancer Chemother. Pharmacol., 1998, 42, 149-154.
7. Zhong, P. Q.; Zhi, F. X.; Li, R.; Xue, J. L.; Shu, G. Y. Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 1998, 86, 139-144.
8. Kane, S. A.; Natrajan, A.; Hecht, S. M. On the role of the bithiazole moiety in sequence-selective DNA cleavage by Fe.bleomycin. J. Biol. Chem., 1994, 269, 10899-10904.
9. Aouida, M.; Leduc, A.; Poulin, R.; Ramotar, D. AGP2 encodes the major permease for high affinity polyamine import in Saccharomyces cerevisiae. J. Biol. Chem., 2005, 280, 24267-24276.
10. Nagase, T.; Uozumi, N.; Ishii, S.; Kita, Y.; Yamamoto, H.; Ohga, E.; Ouchi, Y.; Shimizu, T. A pivotal role of cytosolic phospholipase A (2) in bleomycin-induced pulmonary fibrosis. Nat. Med., 2002, 8, 480-484.
11. Jani, J. P.; Mistry, J. S.; Morris, G.; Davies, P.; Lazo, J. S.; Sebti, S. M. In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Res., 1992, 52, 2931-2937.
12. Einhorn, L. H. Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. USA, 2002, 99, 4592-4595.
13. Lazo, J. S.; Sebti, S. M.; Schellens, J. H. Bleomycin. Cancer Chemother. Biol. Response Modif., 1996, 16, 39-47.
14. Levi, J. A.; Raghavan, D.; Harvey, V.; Thompson, D.; Sandeman, T.; Gill, G. et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J. Clin. Oncol., 1993, 11, 1300-1305.
15. Robertson, K. A.; Bullock, H. A.; Xu, Y.; Tritt, R.; Zimmerman, E.; Ulbright, T. M.; et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res., 2001, 61, 2220-2225.
16. Gottesman, M. M.; Hrycyna, C. A.; Schoenlein, P. V.; Germann, U. A.; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 1995, 29, 607-649.
17. Decottignies, A.; Goffeau, A. Complete inventory of the yeast ABC proteins. Nat. Genet., 1997, 15, 137-145.
18. Jani, J. P.; Mistry, J. S.; Morris, G.; Lazo, J. S.; Sebti, S. M. In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncol. Res., 1992, 4, 59-63.
19. Pei, Z.; Calmels, T. P.; Creutz, C. E.; Sebti, S. M. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells. Mol. Pharmacol., 1995, 48, 676-681.
20. Wang, H.; Ramotar, D. Cellular resistance to bleomycin in Saccharomyces cerevisiae is not affected by changes in bleomycin hydrolase levels. Biochem. Cell Biol., 2002, 80, 789-796.
21. Zheng, W.; Xu, H. E.; Johnston, S. A. The cysteine-peptidase bleomycin hydrolase is a member of the galactose regulon in yeast. J. Biol. Chem., 1997, 272, 30350-30355.
22. Zimny, J.; Sikora, M.; Guranowski, A.; Jakubowski, H. Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J. Biol. Chem., 2006, 281, 22485-22492.
23. Aouida, M.; Page, N.; Leduc, A.; Peter, M.; Ramotar, D. A genome-wide screen in saccharomyces cerevisiae reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin. Cancer Res., 2004, 64, 1102-1109.
24. Pron, G.; Belehradek, J.; Jr., Mir, L. M. Identification of a plasma membrane protein that specifically binds bleomycin. Biochem. Biophys. Res. Commun., 1993, 194, 333-337.
25. Steinmetz, L. M.; Scharfe, C.; Deutschbauer, A. M.; Mokranjac, D.; Herman, Z. S.; Jones, T.; Chu, A. M.; Giaever, G.; Prokisch, H.; Oefner, P. J.; Davis, R. W. Systematic screen for human disease genes in yeast. Nat. Genet., 2002, 31, 400-404.
26. Chang, M.; Bellaoui, M.; Boone, C.; Brown, G. W. A genome-wide screen for methyl methanesulfonate-sensitive mutants reveals genes required for S phase progression in the presence of DNA damage. Proc. Natl. Acad. Sci. USA, 2002, 99, 16934-16939.
27. Berg, K.; Dietze, A.; Kaalhus, O.; Hogset, A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin. Cancer Res., 2005, 11, 8476-8485.
28. van Roermund, C. W.; Hettema, E. H.; van den Berg, M.; Tabak, H. F.; Wanders, R. J. Molecular characterization of carnitinedependent transport of acetyl-CoA from peroxisomes to mitochondria in Saccharomyces cerevisiae and identification of a plasma membrane carnitine transporter, Agp2p. EMBO. J., 1999, 18, 5843-5852.
29. Aouida, M.; Khodami-Pour, A.; Ramotar, D. Novel role for the Saccharomyces cerevisiae oligopeptide transporter Opt2 in drug detoxification. Biochem. Cell Biol., 2009, 87, 653-661.
30. Cullis, P. M.; Green, R. E.; Malone, M. E.; Merson-Davies, L.; Weaver, R. Targeting of tumour cells with polyamine-drug conjugates. Biochem. Soc. Trans., 1994, 22, 402S.
31. Enomoto, A.; Wempe, M. F.; Tsuchida, H.; Shin, H. J.; Cha, S. H.; Anzai, N.; Goto, A.; Sakamoto, A.; Niwa, T.; Kanai, Y.; Anders, M. N.; Endou, H. Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J. Biol. Chem., 2002, 277, 36262-36271.
32. Tamai, I.; Ohashi, R.; Nezu, J.; Yabuuchi, H.; Oku, A.; Shimane, M.; Sai, Y.; Tsuji, A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem., 1998, 273, 20378-20382.
33. Aouida, M.; Poulin, R.; Ramotar, D. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J. Biol. Chem., 2010, 285, 6275-6284.
34. Canellos, G. P. Lymphoma: present and future challenges. Semin. Hematol., 2004, 41, 26-31.
35. Okabe, M.; Unno, M.; Harigae, H.; Kaku, M.; Okitsu, Y.; Sasaki, T, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun., 2005, 333, 754-762.
36. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 2007, 24, 1227-1251.
37. Gong, S.; Lu, X.; Xu, Y.; Swiderski, C. F.; Jordan, C. T.; Moscow, J. A. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp. Hematol., 2002, 30, 1162-1169.
38. Sato, N.; Ito, K.; Onogawa, T.; Akahira, J.; Unno, M.; Abe, T.; et al. Expression of organic cation transporter SLC22A16 in human endometria. Int. J. Gynecol. Pathol., 2007, 26, 53-60.
39. Goossens, A.; de La Fuente, N.; Forment, J.; Serrano, R.; Portillo, F. Regulation of yeast H (+)-ATPase by protein kinases belonging to a family dedicated to activation of plasma membrane transporters. Mol. Cell Biol., 2000, 20, 7654-7661.
40. Sanz, G.; Mir, L.; Jacquemin-Sablon, A. Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene. Cancer Res., 2002, 62, 4453-4458.
41. Lamhonwah, A. M.; Ackerley, C. A.; Tilups, A.; Edwards, V. D.; Wanders, R. J.; Tein, I. OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochem. Biophys. Res. Commun., 2005, 338, 1966-1972.
42. Zhang. S.; Lovejoy, K. S.; Shima, J. E.; Lagpacan, L. L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komari, T.; Gray, J. W.; Chen, X.; Lippard, S. J.; Giacomini, K. M. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res., 2006, 66, 8847-8857.